Free Newsletter
Merck unveils $3.7M in doc-payment data
Big Pharma's march toward doc-disclosure proceeds apace. Merck posted its first list of speaking fees paid to doctors and other health professionals, detailing some $3.7 million in payments for the third quarter. On average, Merck paid 1,078 speakers $1,548, the Associated Press calculates. But the top-paid doc raked in more than $22,000, and a dozen were paid at least $17,000.
For comparison's sake, we looked back at Eli Lilly's first doc-payment posting; the top-paid doc on Lilly's list earned $70,050 and its second-highest paid got $68,400. Plus, the total of first-quarter payments reached $22 million, compared with Merck's $3.7 million.
We'll soon get more drugmaker numbers to compare and contrast; GlaxoSmithKline says it's joining the disclosure club soon, and so is Pfizer. And as you may also recall, not all these companies are doing the disclosure thing voluntarily. Some were compelled to start detailing their doc payments as part of off-label marketing settlements.
- see the release from Merck
- read the Merck payment list
- check out the AP story
Related Articles:
Merck CEO: "Totally transparent" on doc dollars
Merck joins Lilly in disclosure pledge
Doc disclosure gets boost from AZ, Merck
Congress mandates disclosure
Editor's note: This story was updated on October 21, 2009.
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: